ProBioGen and Pionyr Immunotherapeutics initiate second collaboration
Collaboration in contract development and manufacturing
Advertisement
ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will perform process development and GMP manufacturing on a second antibody from the Pionyr pipeline using their high performance CHO.RiGHT® expression platform. Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline, enabling a rapid advance to clinical trials.
“We developed a strong collaboration with Pionyr Immunotherapeutics on their initial antibody candidate, and we are enthusiastic about advancing a second antibody candidate into development. We consider Pionyr’s Myeloid Tuning™ approach to be ideally suited to target solid tumors and look forward to contributing to multiple programs with our CHO.RiGHT® development and manufacturing platform. We have established a seamless team working across the two companies and are very pleased to expand our collaboration”, said Dr René Brecht, VP Process Science and Manufacturing.
Other news from the department business & finance
These products might interest you
Tailor-made products for specific applications by IPC Process Center
Granulates and pellets - we develop and manufacture the perfect solution for you
Agglomeration of powders, pelletising of powders and fluids, coating with melts and polymers
Custom qPCR and dPCR primers and PCR assay development. by Microsynth
Assay Design, Validation and Analysis - Primers and Probes for qPCR and dPCR Applications
High-quality qPCR and dPCR probes, extensive experience in assay design, development and validation
